Cisplatin liposomal inhaled - Eleison Pharmaceuticals

Drug Profile

Cisplatin liposomal inhaled - Eleison Pharmaceuticals

Alternative Names: ILC; Inhaled cisplatin - Insmed; Inhaled lipid cisplatin; Inhaled lipid-complexed cisplatin (ILC); Lipid cisplatin complex

Latest Information Update: 21 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Insmed
  • Developer Eleison Pharmaceuticals
  • Class Antineoplastics; Platinum complexes
  • Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cancer metastases; Osteosarcoma

Most Recent Events

  • 11 Dec 2015 Eleison receives patent allowance for lipid-complexed cisplatin United States
  • 24 Jun 2015 Cisplatin liposomal inhaled is still in phase II trials for Osteosarcoma with Cancer metastases (In adolescents, Prevention of relapse, Second-line therapy or greater) in the USA
  • 19 Jan 2015 Inhaled liposomal cisplatin sub-licensed to Intelgen in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top